Cancers are currently diagnosed, categorised, and treated based on their tissue of origin.
Introduction
Tumors have traditionally been classified into histological subtypes primarily based on their anatomical site of origin (organs or tissues). Although certain mutations (e.g., TP53, PIK3CA), somatic copy number aberrations (e.g., the MYC locus), and gene expression patterns (e.g., basal) are common to several cancer types, cancers are usually described according to their histological differences rather than their molecular and cellular similarities.
We propose a different approach in which cancers are regarded according to a cell-of-origin/phenotype model based on tissue architecture and molecular similarities: a heterocellular mix of basal/myoepithelial, epithelial/luminal, immune, connective tissue, and stem cells 1 . Systematic molecular mapping of tissue heterotypia across different cancer types helps to appreciate how the molecular correlates of tissue morphology affect the cancer phenotype and expression of therapeutic targets.
Here we test the hypothesis that common heterocellular signatures across different epithelial cancers define consensus tissue-independent subtypes harbouring common cancer pathways and somatic aberrations. Defining consensus heterocellular subtypes provides opportunities for personalised diagnosis and treatment across the entire epithelial cancer spectrum by establishing common drug targets that may be potentially exploited by repositioning existing drugs. We achieved this by constructing consensus heterocellular subtypes based on our colorectal cancer (CRC) gene expression subtypes (CRCassigner;
enterocyte, goblet-like, inflammatory, stem-like, and transit-amplifying (TA) 2 ), since these already represent different cells occupying normal and diseased colonic crypts 2 . Also, the FDA has approved the most drugs for CRC 3 , providing broader scope for rapid drug repositioning into other cancers.
Using CRCassigner gene expression signatures to reclassify other epithelial cancer types, we show that these five heterocellular subtypes are prevalent in other cancers. Consequently, we could characterise immune enrichment, microsatellite instability (MSI), and mutational enrichment in tumours from different epithelial cancers using CRC subtypes as surrogates.
The molecular features previously thought to be specific for CRC are present in other cancers and can be exploited to select the most appropriate therapy irrespective of cancer type.
Results and Discussion

Presence and variability of CRC subtypes across different epithelial tumours
We sought to reclassify individual epithelial cancers as consensus heterocellular subtypes reflecting the overall tissue/cellular architecture ( Figure 1A ). We started with the Second, some variability may be dataset specific, so we validated the presence of the CRC heterocellular subtypes in other gastric cancer 6,10 (three datasets; n=363), pancreatic cancer 11 (n=36), colorectal 12 (n=288), ovarian 5 (n=259), lung 13 (LAUD and LUSC; n=168), and breast 14 (n=104) datasets (Supplementary Figure 1F and Supplementary Table A-F).
The enterocyte subtype was not present in ovarian 5 or kidney 5 cancers and was present only in a small proportion of other cancers, probably because enterocytes are highly specialised, terminally differentiated, and present only in the small intestine and stomach (Supplementary Figure 1F and Supplementary Table 1E-F) . For the same reason, the goblet-like subtype was uncommon in kidney (0.6%) and lung squamous cell cancers (0.4%;
Supplementary Table E-F) . However, at least four CRC heterocellular subtypes were present in the majority of cancer types.
Third, tissue-specific genes might contribute to heterocellular subtype variability across cancer types, so we shrunk the CRCassigner signature into 564 (CRCassigner-564) genes specific for each subtype using PAM centroid scores (Supplementary Table 1H ) and compared them to colon-specific genes (n=198; present in expressed sequence tag; Supplementary Table 1I ) from the tissue-specific database 15 (TiGER). The goblet-like subtype had the highest percentage of colon-specific genes (12.5%, n=6) followed by enterocyte (10.3%, n=8) and TA (8.4%, n=13) subtypes ( Figure 1E and Supplementary Figure 1E and Supplementary Table 1J) , accounting for the high variability of these subtypes across cancer types (Supplementary Figure 1F-I) . Conversely, none of the stemlike subtype marker genes and only one from the inflammatory subtype were colon specific.
The remaining gene signature (n=222) shared by two or more subtypes contained 9% of the colon-specific genes, further contributing to variability. Overall, at least four heterocellular subtypes were similar across cancer types while their proportions varied depending on the functional and tissue-specific characteristics.
Comparison of heterocellular subtypes to known intrinsic subtypes in multiple cancer types
Tissue-specific cancers are now commonly subdivided into different heterocellular subtypes.
To further understand which heterocellular subtypes correspond to which intrinsic cancer subtypes, we compared heterocellular subtypes with the original published/known subtypes for different cancers. There were significant associations for ten cancer types (chi-squared test; p<0.0001, Figure 1E and Supplementary Figure 1E ).
Therefore, although some associations between heterocellular and intrinsic subtypes were variable across cancer types, the core tissue heterotypia described by heterocellular subtypes was reflected in the existing molecular subtypes, i.e., epithelial/mesenchymal, differentiated/undifferentiated/stemness, or luminal/basal/stemness. Given that heterocellular subtypes did not perfectly match existing subtypes, we further analysed what emergent biology was discernible in different cancer types given the heterocellular classification.
Pancreatic cancer subtypes
We previously described three intrinsic pancreatic adenocarcinoma gene expression 
Gastric cancer subtypes
We next compared our heterocellular subtypes to the intrinsic gastric cancer subtypes defined by Lei et al. 
Heterogeneity in MSI cancers dictated by heterotypic subtypes and the immune microenvironment
We sought to explore whether our heterocellular subtypes show similar therapeutic and molecular features to their parent subtypes. We previously showed that inflammatory subtype CRCs were significantly enriched for microsatellite instable (MSI) 2 , so we reasoned that similar enrichment for MSI would be present in other cancer types (Figure 3C-E and Supplementary Table 3A-I) . Similar to CRC (TCGA) inflammatory samples with greater than 75% MSI (both MSI-H and MSI-L, Figure 3C ), the inflammatory subtype in gastric (stomach;
TCGA STAD, Figure 3D ) and endometrial (TCGA UCEC, Figure 3E ) cancers had >40%
MSI. The goblet-like subtype had about 40% MSI (mostly MSI-L) and, similarly, the gobletlike cancers from both TCGA STAD and UCEC showed the second highest proportion of MSI samples.
Multiple studies 21, 22 have suggested that MSI tumours could be susceptible to immune checkpoint blockade, so we compared the expression of immune genes between the MSI samples from goblet-like and inflammatory subtypes across the three cancer types. 24 that KRAS-independent cells have more EMT-like phenotypes. Therefore, any therapy that is effective in goblet-like-dependent or stem-likeindependent KRAS mutation samples may be applicable to the other two cancers with the same profiles.
Luminal breast cancer heterogeneity associated with progenitor cells
The basal-like breast cancer and HER2-enriched subtypes 26 Figure 5F ).
Conclusion
Here we successfully classified multiple cancer types into five tissue-independent CRC subtypes based on the main cell types present in the colonic crypt. While the majority of cancer types were significantly classified into stem-like and inflammatory subtypes, not all cancer types were readily classified into enterocyte and goblet-like subtypes due to their colon specificity. It is unknown why a certain subset of tissue-independent genes are not dynamically expressed in cancers that are physically or functionally unrelated to the colorectum, but it might be because the majority of CRCassigner genes were those normally associated with normal gastrointestinal-related organs.
This reclassification approach serves to characterise additional heterogeneity in different cancer types, for example three new subtypes in PC. Similarly, we were able to identify additional gene expression-based heterogeneity in the luminal A breast cancer subtype and heterogeneity in MSI or KRAS mutant cancers using CRC subtypes as surrogates. MSI in CRC, GC, and UCEC has previously unidentified heterogeneity not only defined by inflammatory and goblet-like genes but also stemness. Finally, KRAS mutations in CRC, PC, and lung cancer are heterogeneous and have different dependencies in different subtypes.
Overall, these sub-subtypes and the discovery of further heterogeneity defined by consensus heterocellular signatures are useful for diagnostic stratification and to personalise new and existing treatments to shared molecular features in different cancer types. 
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